Author:
,Jacoby Robin,Lunn A. Daniel,Ardern M.,Bergmann K.,Conway J.,Cooling N.,Davies G.,Fisk J.,Gehlhaar E.,Harrison-Read P.,Hawley R.,Jacoby R.,Jones R.,Levy R.,MacDonald A.,Naguib M.,Oppenheimer C.,Philpot M.,Philpott R.,Pitt B.,Price M.,Robinson J.,Silverman M.,Simons R.,Slattery Z.,Staley C.,Taws E.,Tym E.,White M.,
Abstract
Of 219 elderly patients with a major depressive disorder (meeting RDC), 69 recovered sufficiently and consented to enter a two-year double-blind placebo-controlled trial of dothiepin. Survival analysis revealed that dothiepin reduced the relative risk of relapse by two and a half times. Past but not current serious physical illness was also associated with a favourable outcome, whereas a prolonged index depressive illness trebled the relative risk of relapse. In the light of previous research on prognosis it is suggested that elderly persons who recover from a major depressive illness should continue with antidepressant medication for at least two years, if not indefinitely.
Publisher
Royal College of Psychiatrists
Subject
Psychiatry and Mental health
Cited by
111 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献